News >

Expert Emphasizes Importance of Acalabrutinib Approval in MCL

Angelica Welch
Published: Thursday, Dec 14, 2017

There is an international phase III study of rituximab (Rituxan) plus or minus acalabrutinib versus placebo. Many more combinations will come in time. 

In your mission to cure MCL, what are some challenges ahead?

We must advance the science to understand the disease even better, and develop great medicines, such as ibrutinib (Imbruvica), acalabrutinib, bortezomib (Velcade), and lenalidomide (Revlimid). After a while, however, the patient will, inevitably, develop resistance. Therefore, our number 1 enemy is resistance and the only way to overcome it is through science and technology. 

What should community oncologists know about acalabrutinib now that it is commercially available?

For community oncologists and hematologists, remember the name acalabrutinib, and know it is FDA-approved for relapsed MCL—that is all they need to know. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication